Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects

British Journal of Clinical Pharmacology

Volumn 56, Issue 1, 2003, Pages 39-45

  Ferron, Geraldine M ^a   Patat, Alain ^b   Parks, Virginia ^b   Rolan, Paul ^c   Troy, Steven M ^a,c  

^a PFIZER INC   (United States)

^b Clinical Research and Development   (France)

^c Medeval Ltd   (United Kingdom)

Author keywords

Antiepileptics; Drug interaction; Glucuronidation; Induction; Phenobarbitone; Retigabine

Indexed keywords

AWD 21360; DRUG METABOLITE; PHENOBARBITAL; RETIGABINE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG TOLERABILITY; ELECTROCARDIOGRAM; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; OPEN STUDY; PRIORITY JOURNAL; STEADY STATE;

ADULT; ANTICONVULSANTS; CARBAMATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; PHENOBARBITAL; PHENYLENEDIAMINES; PROSPECTIVE STUDIES;

EID: 0037660846     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01825.x     Document Type: Article

References (23)

1. Rundfeldt CNR. Investigations into the mechanism of action of the new anticonvulsant retigabine. Arzneimittel Forsch Drug Res 2000; 50: 1063-1070.
2. Wickenden AD, Yu W, Zou A, Jegla T, Wagoner PK. Retigabine a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol Pharmacol 2000; 58: 591-600.
3. Tatulian L, Delmas P, Abogadie FC, Brown DA. Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine. J Neurosci 2001; 21: 5535-5545.
4. Rostock A, Tober C, Rundfeldt C, et al. D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res 1996; 23: 211-223.
5. Armand V, Rundfeldt C, Heinemann U. Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by low magnesium in rat entorhinal cortex hippocampal slices. Epilepsia 2000; 41: 28-33.
6. ++ model in the hippocampal slice preparation. Epilepsy Res 2000; 38: 53-66.
7. Straub H, Kohling R, Hohling J, et al. Effects of retigabine on rhythmic synchronous activity of human neocortical slices. Epilepsy Res 2001; 44: 155-165.
8. De Sarro G, Di Paola ED, Conte G, Pasculli MP, De Sarro A. Influence of retigabine on the anticonvulsant activity of some antiepileptic drugs against audiogenic seizures in DBA/2 mice. Naunyn-Schmiedebergs Arch Pharmacol 2001; 363: 330-336.
9. Hempel R, Schupke H, McNeilly PJ, et al. Metabolism of retigabine (D-23129), a novel anticonvulsant. Drug Metab Dispos 1999; 27: 613-622.
10. Ferron GM, Paul J, Fruncillo R, et al. Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers. J Clin Pharmacol 2002; 42: 175-182.
11. Levy R, Wilensky A, Anderson G. Carbamazepine, valproic acid, phenobarbital and ethosuximide. In Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring, 3rd edn, eds Evans WE, Schentag JJ, Jusko WJ. Vancouver, WA. Applied Therapeutics; 1992.
12. Reidenberg P, Glue P, Banfield CR, et al. Effects of felbamate on the pharmacokinetics of phenobarbital. Clin Pharmacol Ther 1995; 58: 279-287.
13. Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. Clin Pharmacokinet 1996; 31: 198-214.
14. Gidal BE, Anderson GD, Rutecki PR, Shaw R, Lanning A. Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy. Epilepsy Res 2000; 42: 23-31.
15. Knebel NG, Grieb S, Leisenheimer S, Locher M. Determination of retigabine and its acetyl metabolite in biological matrices by on-line solid-phase extraction (column switching) liquid chromatography with tandem mass spectrometry. J Chromatogr B Anal Teehnol Biomed Life Sci 2000; 748: 97-111.
16. Rowland M, Tozer T. Clinical pharmacokinetics: concepts and applications, 2rid edn. Philadelphia, PA. Lea & Febiger; 1989.
17. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15: 657-680.
18. French JA, Gidal BE. Antiepileptic drug interactions. Epilepsia 2000; 41: S30-S36.
19. Benedetti MS. Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies. Fundam Clin Pharmacol 2000; 14: 301-319.
20. Riva R, Albani F, Contin M, Baruzzi A. Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations. Clin Pharmacokinet 1996; 31: 470-493.
21. Rambeck B, Specht U, Wolf P. Pharmacokinetic interactions of the new antiepileptic drugs. Clin Pharmacokinet 1996; 31: 309-324.
22. Cloyd JC, Remmel RP. Antiepileptic drug pharmacokinetics and interactions: impact on treatment of epilepsy. Pharmacotherapy 2000; 20: 139S-151S.
23. Ferron GM, Sachdeo R, Partiot A, Fritz T, Althouse S, Troy S. Pharmacokinetic interaction between valproic acid, topiramate, phenytoin or carbamazepine and retigabine in epileptic patients. Clin Pharmacol Ther 2001; 69: 18.